Passage Bio Welcomes Tom Kassberg to the Board of Directors
Passage Bio, Inc. (Nasdaq: PASG), a leading company dedicated to developing genetic medicines for neurodegenerative diseases, is thrilled to announce that Tom Kassberg has joined its Board of Directors. In addition to his new role, Kassberg will also serve on the Audit Committee, where he will bring a wealth of expertise to the organization.
Tom Kassberg's Experience and Leadership Qualities
Currently, Mr. Kassberg is the Chief Business Officer and Executive Vice President at Ultragenyx, a firm focused on creating innovative therapies for rare genetic disorders. His extensive background in business development and alliance management has been crucial in advancing various treatments, including several gene therapies that are currently in later-stage development. This experience positions him as a vital asset to Passage Bio during this important phase for the company.
Leadership Quotes
Will Chou, M.D., president and CEO of Passage Bio, shared his excitement about Kassberg's appointment: "We are delighted to welcome Tom Kassberg to the Passage Bio Board of Directors. He will play a key role in propelling our mission forward during this crucial time for our organization. His profound understanding of strategic planning and corporate development equips him exceptionally well to guide Passage Bio as we advance PBFT02 across various neurodegenerative indications. We are excited to have him on our team."
Kassberg’s Background in Biotechnology
Before his tenure at Ultragenyx, Kassberg held an executive position at Proteolix, Inc. as the Executive Vice President of Corporate Development, where he led strategic initiatives and business development efforts. Earlier in his career, he served as the Senior Vice President of Corporate Development and Commercial Operations at InterMune, Inc. He co-founded Plexxikon and made significant contributions at SUGEN, playing a pivotal role during its acquisition by Pharmacia. Mr. Kassberg’s career began at Bristol Myers Squibb, where he developed his skills in strategic planning, sales, and financial analysis.
Vision for the Future
Mr. Kassberg expressed his enthusiasm about joining the Board, stating, "I am thrilled to be part of the Passage Bio Board of Directors and to contribute to the company's ongoing growth. The impressive progress of the PBFT02 program and the potential to expand into additional indications underscore Passage Bio’s commitment to making a significant impact in the realm of neurodegenerative diseases. I look forward to working with this exceptional team to advance our promising treatments and positively affect the lives of patients and their families."
About Passage Bio
Passage Bio (Nasdaq: PASG) is at the forefront of genetic medicine, focusing on innovative therapies designed for patients dealing with neurodegenerative diseases. The company’s mission extends beyond merely developing treatments; it aims to fundamentally improve the quality of life for these patients. Its leading candidate, PBFT02, is intended to address conditions like frontotemporal dementia through innovative methods that restore lysosomal function and slow disease progression.
Passage Bio is committed to advancing its groundbreaking work while maintaining a strong dedication to patients and their families who are affected by the devastating effects of neurodegenerative disorders. For more information about Passage Bio’s innovative initiatives, you can visit www.passagebio.com.
Contact Information
If you have further inquiries, please reach out to:
Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com
Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
MikeBeyer@sambrown.com
Frequently Asked Questions
What role is Tom Kassberg taking at Passage Bio?
Tom Kassberg has been appointed to the Board of Directors and the Audit Committee at Passage Bio.
What is the primary focus of Passage Bio?
Passage Bio specializes in developing genetic medicines aimed at combating neurodegenerative diseases.
What is PBFT02?
PBFT02 is Passage Bio's leading product candidate designed to treat frontotemporal dementia by targeting underlying disease mechanisms.
What experience does Kassberg bring to Passage Bio?
Kassberg brings extensive experience in business development and corporate strategy from his previous roles at Ultragenyx and Proteolix, among others.
How can I find more information about Passage Bio?
More information about Passage Bio’s mission and projects can be found on their official website at www.passagebio.com.
